Avidity Biosciences, Inc.
Avidity Biosciences is a company driven by the mission to profoundly improve people's lives by revolutionizing a new class of targeted RNA therapeutics through its Antibody Oligonucleotide Conjugates (AOC™) platform.
Funding history
About Avidity Biosciences, Inc.
How much funding has Avidity Biosciences, Inc. raised?
Avidity Biosciences, Inc. has raised $400.2M in total funding.
Where is Avidity Biosciences, Inc. headquartered?
Avidity Biosciences, Inc. is headquartered in San Diego, CA.
What does Avidity Biosciences, Inc. do?
Avidity Biosciences is a company driven by the mission to profoundly improve people's lives by revolutionizing a new class of targeted RNA therapeutics through its Antibody Oligonucleotide Conjugates (AOC™) platform.
What problem does Avidity Biosciences, Inc. solve?
Rare muscle diseases like myotonic dystrophy (DM1), FSHD, and Duchenne muscular dystrophy (DMD) lack therapies that reach previously inaccessible tissue and address their underlying genetic drivers.
What's Avidity Biosciences, Inc.'s solution?
Avidity is developing Antibody Oligonucleotide Conjugates (AOC), a new class of RNA therapeutics aimed at the root cause of these muscle diseases.
What makes Avidity Biosciences, Inc. different?
Their AOC platform is described as combining the specificity of monoclonal antibodies with the precision of oligonucleotides to reach cell types previously inaccessible to RNA therapeutics.
What makes Avidity Biosciences, Inc. notable?
Novartis completed its acquisition of Avidity Biosciences in 2026, folding the San Diego RNA-therapeutics company into its late-stage neuroscience pipeline.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
